Tanım

Cardiac biomarkers are of great importance in the timely, accurate diagnosis and management of acute coronary syndrome as well as the prognosis. Diagnosis in the golden period is of utmost importance to institute therapy at the earliest and possibly reverse the myocardial damage. Cardiac biomarkers are also a powerful tool for triaging. StratejiHelix'in raporuna göre, the global cardiac biomarkers market is set to increase by US$ 7.1 sırasında milyar 2022-2028, yıllık bileşik büyüme oranıyla büyüyor 9.3% tahmin dönemi boyunca.

Rapor, döneme ilişkin güncel pazar büyüklüğü verilerini sağlar 2018-2021 ve tahmin 2028 covering key market aspects like sales value for cardiac biomarkers. The global cardiac biomarkers market is segmented on the basis of type, location of testing, başvuru, ve bölge. Tür bazında, the global cardiac biomarkers market has been segmented into albumin, creatine kinase-MB (CK-MB), low-density lipoproteins (LDL) and high-density lipoproteins (HDL), myoglobin, natriuretic peptides – B-type natriuretic peptide (BNP) & N-terminal pro b-type natriuretic peptide (NT-proBNP), troponins, diğerleri. By location of testing, the global cardiac biomarkers market has been segmented into laboratory testing, point of care testing. Based on application, the global cardiac biomarkers market is categorized into acute coronary syndrome, atherosclerosis, congestive heart failure, myocardial infarction, diğerleri. coğrafi olarak, the global cardiac biomarkers market is segmented into North America, Asya Pasifik, Avrupa, Dünyanın Geri Kalanı (ROW).

The global cardiac biomarkers market is highly competitive. The cardiac biomarkers market is dominated by key players, which are Abbott Laboratories, ACS Biomarker B.V., bioMerieux S.A., Bio-Rad Laboratories Inc., Danaher Corporation, F. Hoffmann-La Roche AG, Johnson & Johnson, Novartis AG, QuidelOrtho Corporation, Randox Laboratories Ltd., Siemens AG, Thermo Fisher Scientific Inc., Tosoh Bioscience Inc.

Rapor, bu sektörde faaliyet gösteren şirket ve kuruluşlar için paha biçilmez bir kaynaktır. It provides a cohesive picture of the cardiac biomarkers market to help drive informed decision making for industry executives, kural koyucular, akademik, ve analistler.

Rapor Kapsamı

Tip: albumin, creatine kinase-MB (CK-MB), low-density lipoproteins (LDL) and high-density lipoproteins (HDL), myoglobin, natriuretic peptides – B-type natriuretic peptide (BNP) & N-terminal pro b-type natriuretic peptide (NT-proBNP), troponins, diğerleri
Location of testing: laboratory testing, point of care testing
Başvuru: acute coronary syndrome, atherosclerosis, congestive heart failure, myocardial infarction, diğerleri
Bölge: Kuzey Amerika, Asya Pasifik, Avrupa, Dünyanın Geri Kalanı (ROW)
Dikkate alınan yıllar: bu rapor dönemi kapsamaktadır 2018 ile 2028

Paydaşlar için Temel Faydalar

– Get a comprehensive picture of the global cardiac biomarkers market
– Büyüme sektörlerini ve yatırım eğilimlerini belirleyin

İçindekiler

Parça 1. giriiş
– Çalışmanın kapsamı
– Çalışma periyodu
– Coğrafik kapsam
– Araştırma metodolojisi
Parça 2. Cardiac biomarkers market overview
Parça 3. Market breakdown by type
– Albumin
– Creatine kinase-MB (CK-MB)
– Low-density lipoproteins (LDL) and high-density lipoproteins (HDL)
– Myoglobin
– Natriuretic peptides – B-type natriuretic peptide (BNP) & N-terminal pro b-type natriuretic peptide (NT-proBNP)
– Troponins
– Diğerleri
Parça 4. Market breakdown by location of testing
– Laboratory testing
– Point of care testing
Parça 5. Market breakdown by application
– Acute coronary syndrome
– Atherosclerosis
– Congestive heart failure
– Myocardial infarction
– Diğerleri
Parça 6. Market breakdown by region
– Kuzey Amerika
– Asya Pasifik
– Avrupa
– Dünyanın Geri Kalanı (ROW)
Parça 7. Anahtar şirketler
– Abbott Laboratories
– ACS Biomarker B.V.
– bioMerieux S.A.
– Bio-Rad Laboratories, A.Ş..
– Danaher Corporation
– F. Hoffmann-La Roche AG
– Johnson & Johnson
– Novartis AG
– QuidelOrtho Corporation
– Randox Laboratories Ltd.
– Siemens AG
– Thermo Fisher Scientific Inc.
– Tosoh Bioscience, A.Ş..
StratejiHelix Hakkında
Sorumluluk reddi beyanı